explore -WSS

explore

author：focus 2025-09-28 23:30:00 - browse：1675

Sammy Kimball for STAT

Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Senate panel puts off hardest PBM reforms for another day

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

CDC Director Mandy Cohen on transparency, trust, and health

Rise in cancer among younger people worries and puzzles doctors

Pregnancy ages women, but effects reverse after delivery

With Wegovy coverage, Medicare patients may face high costs

Pregnancy ages women, but effects reverse after delivery

entertainment

explore

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

Asbestos ban is immediate, but health effects will linger for decades

23andMe had bad news about my health. I wish a person had delivered it

How doctors’ personal politics affect patients

Medicare details structure of new drug price negotiation program

Medical devices makers are asking for forgiveness, not permission

Virginia high school admissions case could be legal follow

What to watch for from Zogenix and Amicus clinical trials

How one medical school became remarkably diverse

UHS says company favors patients whose insurance pays more

hotspot

Democrats decry new health bill for going easy on private equity

Yancopoulos of Regeneron works to expand Dupixent success

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Former reverend arrested for allegedly killing 8

Diabetes management: Digital health tools fall short, study says

hotspot

focus

hotspot

focus